With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...
The new "triple agonist" weight loss medication called retatrutide can help people lose an average of 28.7 percent of ...
In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
US health technology assessor the Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report ...
LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.
Starting in 2026, people who are insured through Medicare will pay no more than $2,100 out of pocket on prescription drugs ...
Bariatric doctors who regularly prescribe GLP-1s share how long the worst Ozempic side effects last, and the best ways to ...
At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...
Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity ...
Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback